Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-Therapy.

Trial Profile

Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-Therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 05 Jun 2009 Actual patient number (8) added as reported by ClinicalTrials.gov.
    • 04 May 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top